In this article published in Drug Development & Delivery, Pascale Diesel and Lev Gerlovin discuss how as industry works to advance cell and gene therapy development, the debate over new approaches to structuring and financial clinical research continues.
Click here to read the article.
Navigating competitive arenas in rare disease
Treatment choice is beneficial for people living with rare diseases (RDs) and competition can drive important economic advantages for payers.